Acronis Earns 5-Star Rating in 2023 CRN® Partner Program Guide
This exclusive recognition is awarded to successful and committed channel-focused vendors in the IT space
BURLINGTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Acronis, a global leader in cyber protection, today announced that CRN®, a brand of The Channel Company, has named the Acronis #CyberFit Partner Program with a prestigious 5-star rating in its 2023 Partner Program Guide.
This annual guide offers essential information to solution providers such as managed service providers (MSPs), value-added resellers (VARs), systems integrators, and strategic service providers as they explore technology manufacturers’ partner programs to find the vendors that will best support their business needs. The 5-star rating is awarded to the companies that go above and beyond in their commitment to nurturing strong, profitable, successful channel partnerships.
“We strive to make the Acronis #CyberFit Partner Program an easy, transparent, and powerful business development tool for our partners,” said Alex Ruslyakov, Channel Chief, Acronis. “As a channel-focused company, we’re proud to be recognized with a 5-star rating by CRN, and will continue to deliver value to our partners and invest in their growth – we want to grow together with our partners!”
For the channel partner community, a critical factor when assessing which IT manufacturers, service providers, and distributors to team within building world-class technology solutions is the breadth and depth of the partner programs those companies offer. Strong elements such as financial incentives, sales and marketing assistance, training and certification, technical support, and more can set a vendor apart and play a key role in boosting partners’ long-term growth.
In the 2023 CRN Partner Program Guide, vendors were evaluated based on program requirements and offerings such as partner training and education, pre- and post-sales support, marketing programs and resources, technical support, and communication.
“In today’s world, the need for innovation is greater than ever,” said Blaine Raddon, CEO of The Channel Company. “Solution providers seek vendors that can keep pace with their developing business and evolving client needs. CRN’s 2023 Partner Program Guide delivers deep insight into the strengths of each program, spotlighting the vendors dedicated to supporting their partner community and pushing positive change throughout the IT channel.”
The 2023 Partner Program Guide will be featured in the April 2023 issue of CRN and online at www.CRN.com/PPG.
To learn about Acronis’ recognition on the CRN Partner Program Guide, check out the latest blog here: https://www.acronis.com/en-us/blog/posts/crn-partner-program-guide-5-star-award-how-acronis-ensures-the-success-of-its-partners/
About Acronis
Acronis unifies data protection and cybersecurity to deliver integrated, automated cyber protection that solves the safety, accessibility, privacy, authenticity, and security (SAPAS) challenges of the modern digital world. With flexible deployment models that fit the demands of service providers and IT professionals, Acronis provides superior cyber protection for data, applications, and systems with innovative next-generation antivirus, backup, disaster recovery, and endpoint protection management solutions powered by AI. With advanced anti-malware powered by cutting-edge machine intelligence and blockchain based data authentication technologies, Acronis protects any environment - from cloud to hybrid to on premises - at a low and predictable cost.
Acronis is a Swiss company, founded in Singapore. Celebrating two decades of innovation, Acronis has more than 2,000 employees in 45 locations. Acronis Cyber Protect solution is available in 26 languages in over 150 countries and is used by 18,000 service providers to protect over 750,000 businesses.
About The Channel Company
The Channel Company enables breakthrough IT channel performance with our dominant media, engaging events, expert consulting and education, and innovative marketing services and platforms. As the channel catalyst, we connect and empower technology suppliers, solution providers and end users. Backed by more than 30 years of unequalled channel experience, we draw from our deep knowledge to envision innovative new solutions for ever-evolving challenges in the technology marketplace. www.thechannelcompany.com
Follow The Channel Company: Twitter, LinkedIn, and Facebook.
© 2023 The Channel Company, LLC. CRN is a registered trademark of The Channel Company, LLC. All rights reserved.
The Channel Company Contact:
Natalie Lewis
The Channel Company
nlewis@thechannelcompany.com
Acronis Media Contact:
Karl Bateson
Karl.Bateson@acronis.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8cf23f3f-c037-45a0-8096-61faefa173b5
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n
GOGL - Transactions made under the buy-back program8.6.2023 22:30:00 CEST | Press release
Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back program of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company's common shares in a 12-month period from the announcement. Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has during the week ending Friday June 2, 2023, purchased 25,343 of the Company’s own common stocks. 343 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 80.00 per share and 25,000 of the shares have been bought on Nasdaq at an average price of USD 7.19 per share. Following the completion of the above transactions, GOGL owns a total of 952,428 of own shares, corresponding to 0.47% of the Company’s share capital. An overview of all transactions made under the buy-back program that have been carried out during the above-mentioned date is attached to this repor
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.6.2023 22:00:00 CEST | Press release
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 36,006 divided into 36,006 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are
NORBIT - Enters into a NOK 80 million agreement for contract manufacturing8.6.2023 21:00:00 CEST | Press release
Trondheim, 8 June 2023: NORBIT is pleased to announce that segment PIR has entered into an agreement with an undisclosed Nordic customer for delivery of tailored electronics for data collection and transmission to the clients’ cloud solution. Deliveries are scheduled over a period of 30 months, and the agreement has an estimated value of approximately NOK 80 million over the said period. “The collaboration with this client started with R&D services and industrialisation. With the client’s success in their core market, we are pleased to see that we can enable their industrial scalability from our Selbu factory”, says Per Jørgen Weisethaunet, CEO of NORBIT. For further queries, please contact: Per Jørgen Weisethaunet, CEO, +47 959 62 915 Per Kristian Reppe, CFO, +47 900 33 203 About NORBIT ASA NORBIT is a global provider of tailored technology to selected applications, solving challenges and promoting sustainability through innovative solutions, in line with its mission to Explore More.
Norsk Hydro: Hydro øker prisen midlertidig i tilbudsprosessen for Alumetal8.6.2023 20:06:52 CEST | Pressemelding
Hydro øker tilbudsprisen midlertidig i den pågående tilbudsprosessen for 100 prosent av aksjene i Alumetal til PLN 82,00 per aksje. Den økte tilbudsprisen vil være gjeldende frem til og med 15. juni i år. Hydro tilbyr PLN 82,00 per aksje i Alumetal til alle aksjonærer som tegner seg for salg av aksjer frem til og med kl. 23:59 den 15. juni 2023, herunder de aksjonærene som har tegnet seg for salg av aksjer før prisøkningen trer i kraft (med unntak for ca 32,7 prosent av aksjene eid av IPO30 UNIPESSOAL LDA som vil erverves av Hydro til PLN 78,69 per aksje). Fra og med 16. juni vil tilbudsprisen igjen bli redusert til den opprinnelige prisen på PLN 78,69 per aksje. Den midlertidige prisøkningen tar sikte på å belønne investorer som responderer tidlig i tilbudsprosessen, for å oppfylle Hydros forbehold om kjøp av minimum 50 prosent av aksjene i Alumetal. Omkring 39 prosent av selskapets aksjer er allerede tegnet i tilbudsprosessen, inkludert aksjene som eies av to av medlemmene i Alumetal